Clinical trials: Metastatic Nonsmall Cell Lung Cancer
Non-Small-Cell Lung Cancer
Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC
This is a Prospective, open label, single arm study to evaluate the efficacy and safety of Vebreltinib combined with Osimertinib in the treatment of locally advanced or metastatic non-small cell lung cancer with EGFR 21 L858R…
- Trial name
- NCT06827145
- Testing
- Vebreltinib, Osimertinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- National Cancer Center, China
Cachexia; Cancer, Cachexia
Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC
The purpose of this trial is to learn whether participants who take rilogrotug gain weight, have a better appetite, and have a better quality of life than participants who do not take rilogrotug (placebo arm).
- Conditions
- Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome, Metastatic Colorectal Cancer (CRC)
- Trial name
- REACH (NCT07888075)
- Testing
- Rilogrotug
- Volunteers
- 950 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Carcinoma, Non-Small-Cell Lung
Pemetrexed Plus Gemcitabine for Patients With Locally Advanced or Metastatic NSCLC Who Have Not Had Previous Chemotherapy.
The purposes of this study are to determine: 1. The safety of pemetrexed plus Gemcitabine and any side effects that might be associated with the combination of these two drugs. 2.
- Trial name
- NCT00061464
- Testing
- pemetrexed, gemcitabine
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer, Endometrial Cancer
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
RATIONALE: Vaccines made from a peptide may make the body build an immune response to kill tumor cells. Combining vaccine therapy with interleukin-2 and/or sargramostim may be a more effective treatment for solid tumors.
- Conditions
- Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00019331
- Testing
- aldesleukin, ras peptide cancer vaccine, sargramostim
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Non-squamous Non-small Cell Lung Cancer
Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
This is a non-randomized, open-label, single arm phase II trial of the combination of bevacizumab and ixabepilone in patients with advanced- or metastatic non-squamous NSCLC progressive after first or second-line therapy.
- Trial name
- NCT01057212
- Testing
- ixabepilone, bevacizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Providence Health & Services
Advanced Solid Tumor, Metastatic Colorectal Carcinoma
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of [225Ac]-FPI-2068…
- Conditions
- Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT06147037
- Testing
- FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068
- Where
- 8 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- AstraZeneca
Breast Cancer, Lung Cancer
Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors
RATIONALE: Amifostine may be effective in reducing pain, numbness, tingling, and other symptoms of peripheral neuropathy. PURPOSE: This phase II trial is studying how well amifostine works in reducing pain, numbness, tingling…
- Conditions
- Breast Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer
- Trial name
- NCT00078845
- Testing
- Amifostine
- Where
- 15 sites in United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Non-Small-Cell Lung
Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED)
This is a phase II, randomized, multicenter, open-label study designed to assess the safety and tolerability of concomitant chemotherapy with low-dose temozolomide during whole brain radiation and later on at 14 days on/14 days…
- Trial name
- NCT00266812
- Testing
- Temozolomide and radiotherapy, Whole brain radiotherapy
- Volunteers
- 35 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer
Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy such as docetaxel use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00064012
- Testing
- bortezomib, docetaxel
- Where
- 21 sites in United States
- Volunteers
- 4 people
- Sponsor
- University of Wisconsin, Madison
Lung Cancer, Non-Small Cell
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer
This is a multicenter, randomized, double-blind, placebo-controlled study of niraparib plus pembrolizumab versus placebo plus pembrolizumab as maintenance therapy in participants with advanced or metastatic non-small cell lung…
- Trial name
- ZEAL-1L (NCT04475939)
- Testing
- Niraparib, Pembrolizumab
- Where
- 188 sites in United States, Argentina and 25 more
- Volunteers
- 666 people
- Sponsor
- GlaxoSmithKline
Non-Small Cell Lung Cancer
A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
This study will assess the safety and tolerability, and make a preliminary assessment of activity, of a combination of pertuzumab and erlotinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)…
- Trial name
- NCT02507375
- Testing
- Erlotinib, Pertuzumab
- Where
- 3 sites in Belgium, Spain and 1 more
- Volunteers
- 17 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung, Lung Cancer
A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer
The purpose of this study is to find out if treatment with NEO-PV-01 in combination with pembrolizumab and chemotherapy (pembrolizumab/chemotherapy) is safe and useful for patients with lung cancer.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung
- Trial name
- NCT03380871
- Testing
- NEO-PV-01, Pembrolizumab, Adjuvant
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- BioNTech US Inc.
Non-Small-Cell Lung
Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy
This study was designed to evaluate the role of canakinumab in combination with docetaxel in subjects with advanced non-small cell lung cancer (NSCLC) previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy.
- Trial name
- CANOPY-2 (NCT03626545)
- Testing
- Canakinumab, Docetaxel
- Where
- 78 sites in United States, Argentina and 24 more
- Volunteers
- 245 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer Stage III, Non-Small-Cell Lung Cancer Metastatic
EGFR Mutations on ctDNA in Patients With Advanced NSCLC
The study aims to explore the prevalence of EGFR mutations assessed with ctDNA samples in advanced NSCLC, who had received ≤ 1 prior systemic chemotherapy regimens.
- Trial name
- NCT02623257
- Testing
- mutation detection, ARMS, ctDNA analysis
- Where
- China
- Volunteers
- 1,055 people
- Sponsor
- First People's Hospital of Hangzhou
Advanced or Metastatic NSCLC
A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy
A study to investigate efficacy and safety of ceralasertib plus durvalumab in participants aged ≥ 18 years with advanced or metastatic non-small cell lung cancer whose disease progressed on or after prior anti-PD-(L)1 therapy and…
- Trial name
- LOTOS (NCT05941897)
- Testing
- Ceralasertib, Durvalumab
- Where
- 8 sites in Russia
- Volunteers
- 39 people
- Sponsor
- AstraZeneca
Lung Cancer, Non-small Cell Lung Cancer
Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib
This clinical trial is an open-label, single arm study evaluating the safest dose of lorlatinib in combination with standard of care chemotherapy in participants with metastatic anaplastic lymphoma kinase positive (ALK+) NSCLC…
- Trial name
- NSCLC (NCT05948462)
- Testing
- Lorlatinib, Cisplatin or Carboplatin, Pemetrexed
- Where
- 5 sites in United States
- Sponsor
- SCRI Development Innovations, LLC
Metastatic Non-small Cell Lung Cancer
Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC
The study is a single-arm, multi-center, open-label clinical trial. The study aims to expand the sample size based on the fixed dose recommended by the results of previous dose exploration studies in order to further evaluate the…
- Trial name
- NCT03300115
- Testing
- AC0010
- Where
- 25 sites in China
- Volunteers
- 222 people
- Sponsor
- Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Non-Small Cell Lung Cancer, NSCLC
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
Study STX-721-101/PFL-721CI101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721/PFL-721 in participants with non-small cell lung…
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation
- Trial name
- NCT06043817
- Testing
- STX-721/PFL-721 (Escalated), STX-721/PFL-721 (3 dose levels), STX-721/PFL-721 (RP2D)
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 345 people
- Sponsor
- Pierre Fabre Medicament
Non-small Cell Lung Cancer
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally…
- Trial name
- TROPION-Lung14 (NCT06350097)
- Testing
- Osimertinib, Datopotamab Deruxtecan
- Where
- 167 sites in United States, Australia and 17 more
- Volunteers
- 582 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer, Pancreas Cancer
T Cell Receptor T Cells for Advanced KRAS G12V-mutant Non-small Cell Lung Cancer, Pancreas Cancer, Colon Cancer
This phase I trial studies the side effects and best dose of autologous CD8+ and CD4+ transgenic T cells expressing high affinity KRASG12V mutation-specific T cell receptors (FH-A11KRASG12V-TCR) and to see how well they work in…
- Conditions
- Non-small Cell Lung Cancer, Pancreas Cancer, Colon Cancer
- Trial name
- NCT06043713
- Testing
- Bendamustine, Biopsy, Biospecimen Collection
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Fred Hutchinson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.